Jim Cramer discussed two negative stock stories that have turned positive. Tesla (TSLA) has been a “cult stock” that Cramer has been leery about, but an upgrade from Deutsche Bank points to volume increase and production growth. Those who bet against Tesla because they were afraid of the hype may have missed the initial move, but Tesla isn’t done going higher, because Cramer thinks it is undervalued, especially when considering its accelerating revenue growth. Elon Musk’s other company, Solar City, hasn’t been quite the winner Tesla is, but there might be life in the stock yet.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Mannkind (MNKD) has a promising inhaled insulin treatment, but Cramer was uneasy about the stock, because it didn’t have a partner to invest in the treatment. This changed with its recent deal with Sanofi-Aventis, and while the shorts, which hold 30% of MNKD’s stock are going to fight, Cramer thinks it is going to be a “Pyrrhic victory” for those betting against Mannkind.